Aliskiren

Aliskiren

Treatment option:

Medically reviewed

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aliskiren

Quick Facts

Property	Description
Active ingredient	Aliskiren hemifumarate (INN)
Form	Oral tablet (film-coated)
Pharmacological class	Direct Renin Inhibitor (DRI)
Common use	Lowering high blood pressure (hypertension)
Origin	Synthetic, non-peptide compound

What Type of Medicine Is Aliskiren?

Aliskiren is a synthetic compound that holds a unique position as the first and only medicine belonging to the pharmacological class known as Direct Renin Inhibitors (DRIs). This prescription-only medication is designed to interfere with the body's key system for blood pressure control, the Renin-Angiotensin-Aldosterone System (RAAS). Unlike established antihypertensive drugs like ACE inhibitors or ARBs, Aliskiren acts at the system's initiation point by binding directly to the enzyme renin, effectively halting the cascade at its source.

This unique upstream blockade is clinically recognized for achieving sustained blood pressure lowering by suppressing plasma renin activity. The medicine is primarily prescribed for adults who require effective management of arterial hypertension.

Aliskiren: Composition, Form, and General Purpose

The active component of the medication is Aliskiren hemifumarate, which is a non-peptide small molecule produced synthetically. The medicine is manufactured as an oral, film-coated tablet, establishing the route of administration as oral. It is available both as a single-ingredient product (monotherapy) and in fixed-dose combination formulations with other antihypertensive agents, such as diuretics.

The general purpose of this therapy is to utilize the precise inhibition of renin to interrupt the hormonal forces that contribute to the maintenance of elevated blood pressure in patients. The mechanism allows blood vessels to relax, which is the primary therapeutic benefit sought in the management of hypertension.

Regulatory References

DailyMed Label: Aliskiren Hemifumarate

What side effects are possible with Aliskiren?

Possible Side Effects and Safety Information

Aliskiren’s safety profile, as documented in governmental regulatory labeling, identifies both common, expected adverse reactions and rare, serious risks.

Common and Expected Adverse Reactions

Adverse events with the highest reported frequency (Common: 1% to 10%) include diarrhea (which is explicitly noted as dose-related), dizziness, arthralgia (joint pain), and elevated serum potassium (hyperkalemia).

Other less common reactions (Uncommon: 0.1% to 1%) reported across body systems include cough, hypotension, palpitations, rash, and the potential for new or worsening renal impairment or acute renal failure.

Serious Adverse Reactions

Certain severe reactions are highlighted in regulatory documents due to their clinical significance and requirement for immediate drug discontinuation:

Angioedema: Rapid swelling of the face, tongue, glottis, and/or larynx, which can be fatal. This is reported as a rare event.
Fetal Toxicity: Aliskiren is associated with injury and death to the developing fetus when used during the second and third trimesters of pregnancy.
Acute Renal Failure/Renal Impairment: Sudden decreases in kidney function have been reported.
Anaphylactic Reactions: Severe, whole-body allergic responses have been noted in post-marketing experience.

Safety Constraints and Monitoring

The medicine carries specific regulatory restrictions:

Contraindication in Pregnancy: Use is strictly forbidden during pregnancy.
Contraindication in Diabetes: It must not be administered concomitantly with an ACE inhibitor or an ARB (dual therapy) in patients with diabetes.

Patients on Aliskiren require periodic monitoring of both serum potassium levels and kidney function (renal function/eGFR) to detect potential electrolyte imbalances or decreases in kidney health as defined by official labeling.

Overdose and Emergency Response

The official regulatory information for Aliskiren indicates that the most likely clinical manifestation of an overdosage is a significant drop in blood pressure, known as hypotension. If symptomatic hypotension occurs, the regulatory guidance mandates the initiation of supportive treatment.

Overdose may be associated with severe, potentially life-threatening systemic outcomes. These documented risks include acute renal failure and electrolyte disturbances such as hyperkalemia (high potassium). Severe adverse events like angioedema, which can cause airway obstruction, require immediate emergency management. Official labeling notes that no specific pharmacologic antidote is known for this medicine.

Government-stated guidance requires individuals to seek immediate medical attention for suspected overdosage. Emergency services must be contacted immediately if the person displays critical signs, including collapse, a seizure, trouble breathing, or if they cannot be awakened. Intensive post-overdose monitoring of renal function and serum electrolytes is required for high-risk patients. A regulatory note also highlights the specific risk of overexposure for children aged 2 to less than 6 years due to physiological considerations.

Therapeutic Uses of Aliskiren

What Aliskiren Treats: Main Uses and Benefits

Aliskiren is commonly used to help with essential hypertension, a condition characterized by the sustained elevation of both systolic and diastolic arterial pressure. This therapy is relevant in clinical settings that involve chronic systemic imbalance. The primary therapeutic goal is to support the management of blood pressure in this chronic condition. It is commonly applied in scenarios that require additional management of discomfort associated with systemic imbalance. Managing elevated pressure is considered relevant for easing the risk of serious cardiovascular events, such as stroke and myocardial infarction (heart attack).

The medicine is applied across domains where additional symptomatic support is needed. It is applied in two main scenarios: as a standalone treatment (monotherapy) for adults and certain pediatric patients or as an additive therapy combined with other agents when symptoms create noticeable functional strain. The therapy is relevant for easing hypertension across relevant patient groups. This use may assist with maintaining a sense of stability when symptoms are more noticeable. This medication supports patients by easing symptoms related to heightened physiological activity.

“This therapy assists with maintaining functional stability and helps support the patient during symptomatic periods by easing symptoms related to heightened physiological activity.”

Quick Fact	Description
Relief for Symptoms	Sustained elevation of arterial pressure.
Target Conditions	Essential hypertension (high blood pressure).
Core Benefit	Contributes to easing the overall symptom load via continuous pressure reduction.

Regulatory References

NIH DailyMed Drug Information

Eligibility and Restrictions for Use

Who can and cannot use Aliskiren?

Aliskiren (a direct renin inhibitor) has strict eligibility requirements and contraindications established by regulatory agencies to minimize the risk of serious complications.

Contraindicated Populations	Rationale/Restriction
Diabetic patients	Must not be used in combination with an ACE Inhibitor or an ARB (dual RAAS blockade) due to the risk of severe renal impairment, hypotension, and hyperkalemia.
Pregnancy	Contraindicated in the second and third trimesters due to risk of fetal injury and death. Discontinuation is required immediately upon pregnancy detection.
Pediatric patients < 2 years	Contraindicated due to risk of high drug exposure and toxicity.
Allergy/Angioedema history	Patients with known hypersensitivity to aliskiren or a history of drug-related angioedema.

Age and Other Restrictions:

Aliskiren is approved for use in adults and pediatric patients aged 6 to 17 years (meeting specific weight criteria). Use is not recommended in children aged 2 to 6 years, as safety and efficacy are not established. Use with caution is required in non-diabetic patients with moderate renal impairment (GFR < 60 mL/min) if they are also taking an ACE Inhibitor or ARB, and in patients with volume or salt depletion.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Contraindicated Combinations and Population Constraints

The regulatory profile for Aliskiren establishes mandatory restrictions based on pharmacodynamic and pharmacokinetic mechanisms. The combination of Aliskiren with Angiotensin Receptor Blockers (ARBs) or Angiotensin-Converting Enzyme Inhibitors (ACEIs) is formally contraindicated in patients with diabetes mellitus due to the documented risk of hyperkalemia, hypotension, and renal impairment. This dual RAAS blockade is also advised to be avoided in patients with moderate to severe renal impairment (GFR less than 60 mL/min/1.73 m²). Furthermore, co-administration is contraindicated in children under two years old due to the risk of drug overexposure.

Pharmacokinetic Interference

Aliskiren is a substrate for the P-glycoprotein (P-gp) transporter system. Consequently, potent P-gp inhibitors, such as Cyclosporine and Itraconazole, are contraindicated because they cause a substantial, clinically significant increase in Aliskiren plasma exposure. Conversely, P-gp inducers, including Rifampicin and the herbal product St. John's Wort, are documented to decrease Aliskiren's bioavailability. The combination with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) carries a documented risk of renal impairment and a loss of antihypertensive effect.

Administration Consistency

The interaction profile is sensitive to consistent administration. Patients must consistently adhere to a routine of taking the medication always with or always without food to ensure predictable drug absorption. Furthermore, consumption of Grapefruit Juice or other fruit juices that interfere with absorption is prohibited due to the risk of reduced exposure and potential therapeutic failure.

Mechanism of Action

Direct Upstream Blockade of the Renin-Angiotensin System

Aliskiren functions as a highly targeted direct renin inhibitor, blocking the primary, rate-limiting enzyme in the Renin-Angiotensin-Aldosterone System (RAAS). This mechanistic domain involves the structural prevention of angiotensinogen conversion to Angiotensin I, thereby halting the initiation of the hormonal cascade at its source. This primary action contributes to a subsequent reduction in the activity of systemic signaling within the RAAS.

Cascade Interruption and Physiological Modulation

The upstream blockade leads to a cascade interruption, resulting in reduced circulating levels of the key downstream mediators: Angiotensin II and Aldosterone. The mechanism reduces the influence of these mediators, leading to the physiological effects of vasodilation and decreased fluid retention, which influence the regulation of systemic vascular resistance. By suppressing Plasma Renin Activity (PRA), Aliskiren exerts a targeted influence on the core mechanisms underlying blood pressure modulation, promoting a shift in activity within the humoral pathways that modulate long-term circulatory tone.

Dosage and Administration Information

How Aliskiren Is Used: Official Administration Guidelines

Aliskiren is administered exclusively via the oral route. Its use is defined by specific protocols governing dosage, timing, and form to ensure consistent administration and predictable absorption.

Administration and Dosage Rules

Entity	Official Instruction
Route of Administration	Oral use only (swallowed).
Standard Starting Dose	150 mg once daily for adults.
Maximum Daily Dose	300 mg once daily.
Frequency	Once daily (qDay).

The medicine is supplied as film-coated tablets in 150 mg and 300 mg strengths. The initial adult dose is 150 mg taken once daily. If blood pressure control is inadequate, the dose may be increased, or titrated, to the 300 mg maximum after approximately four weeks, which is the time required to achieve the full therapeutic effect.

Key Administration Conditions

Condition	Instruction
Timing Relative to Meals	Must establish a routine pattern: always take with food or always without food.
Tablets	Must be swallowed whole with water.
Absorption Note	High-fat meals substantially decrease the absorption of the drug.

For administration, patients must maintain a consistent daily routine regarding food intake, as high-fat meals can significantly lower the amount of medicine absorbed. No initial dose adjustment is required for older adults or those with mild to severe hepatic impairment. Dosing for pediatric patients (ages 6 to 17) is determined based on body weight.

Recent Clinical Evidence

Research Evidence for Essential Hypertension

Research has explored Aliskiren for essential hypertension in randomized, placebo-controlled clinical trials conducted over short-term and intermediate-term periods. These studies monitored the measurement of blood pressure change. Trials reported patterns related to measured changes in blood pressure compared to placebo and relative to other established medications. The existing evidence is limited because initial trials primarily focused on blood pressure changes (a surrogate outcome) rather than long-term effects on hard outcomes, such as stroke or heart attack.

Studies in High-Risk Cardiovascular and Renal Contexts

Aliskiren was evaluated in a large-scale, long-term outcome trial (ALTITUDE) in adults with Type 2 Diabetes and high heart/kidney risk already receiving standard therapy. The trial was stopped prematurely. Findings at the time of termination described that the primary outcome (a composite of cardiovascular events and kidney failure) was unlikely to be met. Furthermore, research noted observations related to non-fatal stroke and certain kidney complications were described in the group receiving the study medication. The early cessation of the trial was associated with limited long-term data for this specific population.

Research Evidence in Patients with Heart Failure

Randomized, controlled outcome trials (ASTRONAUT) explored the medicine in patients stabilized following hospitalization for acute heart failure. The primary outcome monitored (cardiovascular death or heart failure re-hospitalization) did not show a measured difference in the observed population. Subgroup findings were mixed. The existing evidence provides limited insight into whether there is a clear pattern of change in hard clinical outcomes when this medicine is added to standard heart failure treatments.

Uncertainty and Research Gaps

Research was conducted to evaluate the medicine in specific populations, including older adults and children (6 to 17), with results applying only to the populations studied in the short-term trials. A key limitation is the lack of completed, controlled studies that tracked patients for a sufficient duration to characterize patterns related to long-term outcomes. Comparative evidence related to long-term outcomes that monitor organ function is lacking.

Key Studies & References

How should Aliskiren be stored and disposed of?

Aliskiren tablets must be stored and handled according to specific regulatory conditions to ensure stability and patient safety.

Storage Conditions

Requirement	Details
Temperature	Store at controlled room temperature, specifically 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C.
Protection	Keep the medicine in its original container, tightly closed. It must be protected from moisture and kept away from freezing temperatures.

Handling and Disposal

For child safety, aliskiren must be stored out of the sight and reach of children.

Unused or expired medication should not be kept. The official disposal procedure requires consultation with a pharmacist or healthcare professional, or following local regulations for drug take-back programs, rather than discarding in household trash or down the drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z